Softgel Capsules Market Size, Share & Trends Analysis Report 2023-2030, Featuring Fuji Capsule, Sirio Pharma, CAPTEK Softgel, Catalent, EuroCaps, Aenova, ProCaps Laboratories and Soft Gel Technologies
Catalent(CTLT.US) Officer Sells US$21,749.4 in Common Stocks
$Catalent(CTLT.US)$ Officer Gunther Scott sold 387 shares of Common Stocks on Mar 15, 2024 at an average price of $56.2 for a total value of $21,749.4.Source: Announcement What is statement of changes
Novo Nordisk Not Planning More Supply Chain Acquisitions: Report
HIGHLIGHTS-Novo Nordisk Hopes to Launch Experimental Obesity Drug This Decade
Novo Nordisk Plans Capex Hike as Backup for Catalent Takeover, CFO Says
Novo Nordisk (NOVO-B.CO) Chief Financial Officer Karsten Munk Knudsen said the company will increase capital expenditure allocation if its takeover of contract drug manufacturer Catalent falls through
Express News | Novo Nordisk CFO Says If Catalent Deal Does Not Close, More Capex Will Be Needed To Build Fill-Finish Capacity Internally
Express News | Novo CMD Says Assuming Catalent Transaction Closes Later This Year, Gross Margin Will Go Down In Coming Years; Novo Nordisk CFO Says We Are Operating On Plan That Catalent Deal Will Close; Our Plan Is Based On Numerous Legal Opinions That Novo And Others
Express News | Novo Nordisk CFO Says If Catalent Deal Does Not Close, Novo Will Also Do More Deals With Contract Drugmakers; Exec Says There Is Still Opportunity To Acquire Companies To Add To Its Obesity Pipeline
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
Commits to reducing Scope 1 and 2 greenhouse gas emissions by 42% from its 2022 baseline by 2030, with commitment to ensuring 70% of supplier emissions have science-based targets by end of fiscal 2028. Implemented
Novo Nordisk Expands Focus to Cardiovascular Disease as Fortunes Soar on Wegovy
Novo Nordisk to Present Early Drug Trial Data, Wegovy Supply Update
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
Eli Lilly (NYSE:LLY) is aggressively pursuing collaborations with outsourcing partners to ramp up the production of its obesity drug, Zepbound (tirzepatide), as it inks deals with key players such as
Eli Lilly Said to Have Tapped National Resilience, BSP for Zepbound Production
Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Twist Bioscience (TWST) and Catalent (CTLT)
Eli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?
The pharma giant Eli Lilly is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into the Fairness of the Acquisition of Catalent, Inc. by Novo Holdings
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
The U.S. stock market continues its unchallenged bull run, with Wall Street notching yet another week of record-breaking highs for the S&P 500 and Nasdaq 100 indices.This ongoing surge demonstrates th
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think (Wall Street Vs. Reddit)
Nvidia Corp. (NASDAQ:NVDA) has undoubtedly emerged as the standout performer among S&P 500 stocks in the initial two months of 2024.While the Santa Clara, California-based tech company enjoyed a 60% g
(CTLT) - Analyzing Catalent's Short Interest
Catalent's (NYSE:CTLT) short percent of float has fallen 33.03% since its last report. The company recently reported that it has 7.45 million shares sold short, which is 5.21% of all regular shares th
Waters, Moderna Most Shorted Stocks in S&P 500 Health Sector Till Jan-end
No Data